COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
23. Dezember 2024 07:45 ET
|
COSCIENS Biopharma Inc.
Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations...
COSCIENS Biopharma Announces Change to Board of Directors
08. Oktober 2024 07:30 ET
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27. August 2024 07:30 ET
|
COSCIENS Biopharma Inc.
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation -...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
23. März 2023 08:05 ET
|
Aeterna Zentaris Inc
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing...
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
10. Januar 2023 08:05 ET
|
Aeterna Zentaris Inc
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
29. August 2022 08:00 ET
|
Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
Aeterna Zentaris Announces Effective Date of Share Consolidation
18. Juli 2022 17:06 ET
|
Aeterna Zentaris Inc
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21. Juni 2022 16:01 ET
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
18. Mai 2022 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...